Macrogenics (MGNX) Change in Acquisitions & Divestments (2016 - 2026)
Macrogenics (MGNX) posted quarterly Change in Acquisitions & Divestments of $47.6 million for Q1 2026, up 159.69% year-over-year from $18.3 million in Q1 2025, and up 106.34% quarter-over-quarter from $23.1 million in Q4 2025.
Analysis
Macrogenics (MGNX) Change in Acquisitions & Divestments (2016 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Change in Acquisitions & Divestments for 11 consecutive years, with $47.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Acquisitions & Divestments rose 159.69% year-over-year to $47.6 million; the TTM figure through Mar 2026 stood at $125.4 million (down 4.7% YoY), while the FY2025 annual figure was $96.1 million, down 49.41% from the prior year.
- Change in Acquisitions & Divestments climbed to $47.6 million in Q1 2026 per MGNX's latest filing, from $23.1 million in the prior quarter.
- Across five years, Change in Acquisitions & Divestments topped out at $76.8 million in Q1 2024 and bottomed at $8.6 million in Q2 2025.
- Historically, Change in Acquisitions & Divestments has averaged $40.6 million across 5 years, with a median of $41.0 million in 2024.
- Annual changes were most pronounced in 2024 — Change in Acquisitions & Divestments jumped 222.29% — and 2025, when it sank 84.77%.
- Macrogenics' Change in Acquisitions & Divestments stood at $39.8 million in 2022, then jumped by 55.75% to $61.9 million in 2023, then tumbled by 74.36% to $15.9 million in 2024, then surged by 45.44% to $23.1 million in 2025, then surged by 106.34% to $47.6 million in 2026.
- Business Quant data shows MGNX's Change in Acquisitions & Divestments at $47.6 million in Q1 2026, $23.1 million in Q4 2025, and $46.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Macrogenics | 284.90 Mn | 171.00 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 61.90 Mn |
| Mar 31, 2026 | 47.64 Mn |
| Dec 31, 2025 | 23.09 Mn |
| Sep 30, 2025 | 46.12 Mn |
| Jun 30, 2025 | 8.59 Mn |
| Mar 31, 2025 | 18.35 Mn |
| Dec 31, 2024 | 15.88 Mn |
| Sep 30, 2024 | 41.00 Mn |
| Jun 30, 2024 | 56.40 Mn |
| Mar 31, 2024 | 76.75 Mn |
| Dec 31, 2023 | 61.91 Mn |
| Sep 30, 2023 | 36.14 Mn |
| Jun 30, 2023 | 17.50 Mn |
| Mar 31, 2023 | 45.75 Mn |
| Dec 31, 2022 | 39.75 Mn |
| Sep 30, 2022 | 72.75 Mn |
| Jun 30, 2022 | 45.43 Mn |
| Mar 31, 2022 | 37.01 Mn |
| Dec 31, 2021 | 54.25 Mn |
| Sep 30, 2021 | 46.75 Mn |